UPB stock forecast, quote, news & analysis
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders... Show more
Why Upstream Bio (UPB) Stock Is Down -48% in the Last 30 Days
Key Takeaways
- UPB shares have dropped roughly 48% over the trailing 30 days, sliding from about $5.36 in late September to $2.79 by late October 2026.
- The selloff has been driven by financing and dilution concerns, a risk-off turn across biotechnology as Treasury yields climbed, and heavy technical selling pressure.
- Positive Phase 2 VALIANT data for verekitug in severe asthma met its primary endpoint, yet the readout was met with selling amid competitive and interpretation concerns.
- Upstream Bio is advancing verekitug into pivotal Phase 3 programs in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), with trials expected to begin in early 2027.
- With roughly $261 million in cash and investments as of mid-2026, the company has guided to a runway into 2027, though Phase 3 funding may require additional capital.
- Elevated short interest and a share price well below its 50-day and 200-day moving averages underscore weak near-term sentiment.
- For additional context on valuation, results, and expectations, explore Upstream Bio's Price Targets, Earnings, and Forecast.
- Discover curated algorithmic trading strategies in Trending AI Robots.
Upstream Bio (UPB) Company Overview and Market Position
Upstream Bio, Inc. (NASDAQ: UPB) is a clinical-stage biotechnology company headquartered in Waltham, Massachusetts. The company is focused on developing therapies for inflammatory and allergic diseases, with an initial emphasis on severe respiratory disorders. Its lead program, verekitug, is the only known antagonist targeting the receptor for thymic stromal lymphopoietin (TSLP) currently in clinical development, positioning the company in a differentiated corner of the immunology field.
Verekitug is being evaluated across severe asthma and CRSwNP, two large indications where established biologic therapies such as Dupixent from Regeneron and Sanofi and Tezspire from Amgen and AstraZeneca already compete. As a single-asset, pre-revenue developer, Upstream Bio is followed closely by investors focused on clinical catalysts, competitive differentiation, and its balance-sheet runway.
Upstream Bio (UPB) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, UPB has fallen roughly 48%, declining from a closing price of $5.36 on September 25, 2026, to $2.79 on October 27, 2026. The move has been punctuated by sharp single-session declines, including an 18.1% drop on October 16 amid a broader risk-off day for equities and biotechnology.
The pullback is part of a longer, multi-month downtrend. Over the trailing quarter, the stock has extended a steep slide from around $7 in late August to below $3, shedding more than half its value. UPB now trades near its 52-week low of roughly $2.68 and far below its 52-week high of $33.68 set in January 2026, while remaining well under its 50-day and 200-day moving averages.
What Drove UPB Stock Price in the Last 30 Days
Several factors converged to pressure the shares. The most prominent was the market's reaction to Upstream Bio's Phase 2 VALIANT data for verekitug in severe asthma. Although the trial met its primary endpoint—showing a meaningful reduction in the annualized asthma exacerbation rate—investors sold the news, reflecting questions about competitive positioning against entrenched biologics and the interpretation of the results.
Financing concerns compounded the pressure. As a single-asset, pre-revenue company planning expensive Phase 3 programs in severe asthma and CRSwNP beginning in early 2027, Upstream Bio faces the prospect of additional equity raises and shareholder dilution despite a cash position of roughly $261 million and a projected runway into 2027.
Analyst sentiment also shifted. JPMorgan downgraded the shares to Neutral and reduced its price target, adding to a de-rating that has persisted across the year. Finally, macro conditions weighed heavily: with the 10-year Treasury yield near 5% and a broader risk-off tone in markets, long-duration, unprofitable biotech names came under outsized selling pressure, amplified by elevated short interest and technical selling.
What Drove UPB Stock Performance Over the Last Quarter
The quarterly decline extends a trend that has shaped UPB for much of 2026. The stock peaked near $33.68 in January 2026 before a sustained repricing driven by the broader de-rating of clinical-stage biotech, rising interest rates, and persistent concerns about single-asset concentration risk.
Across the most recent quarter, investor focus narrowed to the economics of funding the pivotal Phase 3 program. While clinical execution has advanced—Upstream Bio presented VALIANT data and outlined Phase 3 plans—the market has increasingly discounted the value of future, still-uncertain cash flows against near-term dilution risk. The result has been a steady slide toward the 52-week low, with sentiment remaining cautious even as the company's development timeline moves forward.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots from a broader universe of hundreds of bots trading thousands of tickers. Only top-performing and most relevant bots appear in this section, giving traders a focused view of strategies currently gaining traction in the market. The bots vary by strategy, timeframe, and performance metrics, allowing users to compare approaches across different market conditions and asset classes. For investors tracking volatile names like UPB, these tools can provide an additional layer of data-driven insight alongside traditional research. Explore Trending AI Robots to see which strategies are currently standing out.
UPB Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors will monitor several key drivers. The most important near-term items include the initiation and design of the Phase 3 trials for verekitug in severe asthma and CRSwNP, expected to begin in early 2027, and any additional data readouts or regulatory feedback. Funding remains a central focus, with the timing and terms of any future capital raise likely to influence both valuation and sentiment.
Quarterly earnings updates—including the company's next report expected in early November 2026—will offer clarity on cash burn and runway. Macroeconomic conditions, particularly Treasury yields and risk appetite for biotech, will continue to shape price action given the stock's long-duration profile. Competitive developments from established TSLP and broader immunology players also bear watching, as they affect the perceived market opportunity for verekitug.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
UPB in +11.53% Uptrend, advancing for three consecutive days on November 09, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where UPB advanced for three days, in 85 of 103 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where UPB's RSI Oscillator exited the oversold zone, 6 of 11 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 55%.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on UPB as a result. In 20 of 26 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for UPB just turned positive on October 28, 2026. Looking at past instances where UPB's MACD turned positive, the stock continued to rise in 16 of 22 cases over the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 16 of 19 cases where UPB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UPB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
UPB broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for UPB entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.653) is normal, around the industry mean (3.498). P/E Ratio (-1.122) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (91.743) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. UPB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UPB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology